Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amblyomin-X in Advanced Solid Tumors
NCT03120130Phase 1Suspended
- Sponsor
- União Química
- Start
- Feb 2021
- Primary completion
- Aug 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of amblyomin-x in solid tumor (advanced stage) (6 cohorts), sponsored by União Química. Primary endpoint: Grade 4 or non-haematological Grade 3 toxicity at 2 weeks. Started Feb 2021; status: suspended.
02
Drugs
amblyomin-x
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03120130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03120130.